After conducting checks with doctors, ThinkEquity believes that minimally invasive lateral fusion procedures continue to grow despite a challenging environment, while NuVasive's XLIF remains many surgeons' favorite choice for lateral fusion. The firm maintains a $30 target and Buy rating.
After rising 80% in the past seven months, Japan's benchmark Nikkei 225 stock index finally blinked. A staggering …